GGrantIndex
← Leaderboards

Dana M Brantley-Sieders

Vanderbilt University

$4,304,141
Attributed
$7,411,993
Total exposure
5
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY200622
$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$7,411,993 · 5

By mechanism

R01$6,612,693 · 4
K01$799,300 · 1

Top collaborators

Most similar at Vanderbilt University

Same institution · by research overlap

Others in their field

Top investigators on “In Vivo

Research focus

In VivoTumorInvestigationCellsMalignant NeoplasmsMolecularNeoplasm MetastasisTumor GrowthNeoplastic CellSignal TransductionMalignant Breast NeoplasmMouse ModelBlood VesselsGrowthMammary NeoplasmsInhibitor/AntagonistSmall Interfering RnaAnimalsLigandsMediatingCessation Of LifeLinkMammary GlandLung

Grant awards (28)

NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$441,312
R01 · FY2022 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$72,819
R01 · FY2022 · CA
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$617,228
R01 · FY2021 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$450,319
R01 · FY2021 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$74,306
R01 · FY2021 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$450,319
R01 · FY2020 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$74,113
R01 · FY2020 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$436,809
R01 · FY2019 · CA
ephrin-A1 in lipogenesis and breast cancer metastatic progression$46,888
R01 · FY2019 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$464,569
R01 · FY2018 · CA
ephrin-A1 in lipogenesis and breast cancer metastatic progression$379,993
R01 · FY2018 · CA
ephrin-A1 in lipogenesis and breast cancer metastatic progression$379,993
R01 · FY2017 · CA
ephrin-A1 in lipogenesis and breast cancer metastatic progression$379,993
R01 · FY2016 · CA
ephrin-A1 in lipogenesis and breast cancer metastatic progression$189,380
R01 · FY2015 · CA
ephrin-A1 in lipogenesis and breast cancer metastatic progression$188,212
R01 · FY2015 · CA
EphA2 Receptor in Endothelial Cell-Mediated Tumor Progression$165,468
R01 · FY2015 · CA · contact PI
EphA2 Receptor in Endothelial Cell-Mediated Tumor Progression$158,232
R01 · FY2015 · CA · contact PI
ephrin-A1 in lipogenesis and breast cancer metastatic progression$377,592
R01 · FY2014 · CA
EphA2 Receptor in Endothelial Cell-Mediated Tumor Progression$313,989
R01 · FY2014 · CA · contact PI
EphA2 Receptor in Endothelial Cell-Mediated Tumor Progression$304,278
R01 · FY2013 · CA · contact PI
EphA2 Receptor in Endothelial Cell-Mediated Tumor Progression$323,700
R01 · FY2012 · CA · contact PI
EphA2 Receptor in Endothelial Cell-Mediated Tumor Progression$323,181
R01 · FY2011 · CA · contact PI
The role of EphA2 receptor signaling in host-tumor interactions$152,820
K01 · FY2010 · CA · contact PI
The role of EphA2 receptor signaling in host-tumor interactions$152,820
K01 · FY2009 · CA · contact PI
The role of EphA2 receptor signaling in host-tumor interactions$100,000
K01 · FY2009 · CA · contact PI
The role of EphA2 receptor signaling in host-tumor interactions$131,220
K01 · FY2008 · CA · contact PI
The role of EphA2 receptor signaling in host-tumor interactions$131,220
K01 · FY2007 · CA · contact PI
The role of EphA2 receptor signaling in host-tumor interactions$131,220
K01 · FY2006 · CA · contact PI